NCT03617497

Brief Summary

Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a prospective study using long-term EEG monitoring in combination with polysomnography to determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at P50-P75 for not_applicable alzheimer-disease

Timeline
Completed

Started Dec 2020

Longer than P75 for not_applicable alzheimer-disease

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 24, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 6, 2018

Completed
2.3 years until next milestone

Study Start

First participant enrolled

December 1, 2020

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

October 13, 2023

Status Verified

October 1, 2023

Enrollment Period

3.8 years

First QC Date

July 24, 2018

Last Update Submit

October 12, 2023

Conditions

Keywords

Alzheimer DiseaseAlzheimer dementiaEpilepsySleep Wake DisordersEEGPolysomnographyForamen ovale electrodes

Outcome Measures

Primary Outcomes (2)

  • Epilepsy

    presence of epileptic activity

    during EEG recording

  • Sleep wake disorder

    presence of sleep wake disorders

    during polysomnographic recording

Study Arms (3)

Healthy control participants

ACTIVE COMPARATOR

Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography

Diagnostic Test: scalp EEG and polysomnography

Alzheimer disease

ACTIVE COMPARATOR

Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography

Diagnostic Test: scalp EEG and polysomnography

Alzheimer disease with high seizure risk

EXPERIMENTAL

Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography

Diagnostic Test: scalp EEG and polysomnographyDiagnostic Test: scalp EEG with foramen ovale electrodes with polysomnography

Interventions

48 hour 22 channel EEG with polysomnography

Alzheimer diseaseAlzheimer disease with high seizure riskHealthy control participants

long-term scalp EEG with additional foramen ovale electrodes with polysomnography

Alzheimer disease with high seizure risk

Eligibility Criteria

Age55 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant must be able to understand the nature of the study and has the opportunity to have any questions answered. The participant has voluntarily signed the independent Review Board (IRB)/independent Ethics Committee (IEC) approved Informed Consent, prior to the conduct of any study procedures. If the participant is not fully competent, full informed consent must be obtained from a representative and assent must be obtained from the participant.
  • Participant who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable Alzheimer Disease, and have:
  • Clinical Dementia Rating (CDR)-Global Score of 0.5
  • A Mini-Mental State Examination (MMSE) score of 22 to 30
  • Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index (RBANS-DMI) score of 85 or lower
  • Participant has a positive amyloid Positron Emission Tomography (PET) scan.
  • Participant has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
  • Participant has an identified, reliable, study partner (e.g., family member), who has frequent contact with the participant and who will provide information as to the participant's cognitive and functional abilities.

You may not qualify if:

  • Participant has evidence of any other clinically significant neurological disorder other than Alzheimer disease, including but not limited to:
  • Parkinson's disease
  • vascular dementia
  • significant cerebrovascular abnormalities
  • frontal-temporal dementia
  • Huntington's disease
  • normal pressure hydrocephalus
  • brain tumor
  • progressive supranuclear palsy
  • seizure disorder
  • subdural hematoma
  • multiple sclerosis
  • history of significant head trauma followed by persistent neurologic deficits
  • known structural brain abnormalities
  • obstructive sleep apnea syndrome treated with continuous positive airway pressure (CPAP)
  • +13 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Leuven, department of Neurology

Leuven, Vlaams-Brabant, 3000, Belgium

Location

Related Publications (44)

  • Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014 Feb;10(2):115-9. doi: 10.1038/nrneurol.2013.269. Epub 2013 Dec 24.

    PMID: 24366271BACKGROUND
  • Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016 Nov 25;354(6315):1004-1008. doi: 10.1126/science.aah4968.

    PMID: 27885006BACKGROUND
  • Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014 Aug;71(8):971-7. doi: 10.1001/jamaneurol.2014.1173.

    PMID: 24887018BACKGROUND
  • Noebels J. A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia. 2011 Jan;52 Suppl 1(Suppl 1):39-46. doi: 10.1111/j.1528-1167.2010.02909.x.

    PMID: 21214538BACKGROUND
  • Horvath A, Szucs A, Barcs G, Noebels JL, Kamondi A. Epileptic Seizures in Alzheimer Disease: A Review. Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):186-92. doi: 10.1097/WAD.0000000000000134.

    PMID: 26756385BACKGROUND
  • Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med. 2017 Jun;23(6):678-680. doi: 10.1038/nm.4330. Epub 2017 May 1.

    PMID: 28459436BACKGROUND
  • Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013 Sep 1;70(9):1158-66. doi: 10.1001/jamaneurol.2013.136.

    PMID: 23835471BACKGROUND
  • Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol. 2016 Dec;80(6):858-870. doi: 10.1002/ana.24794. Epub 2016 Nov 7.

    PMID: 27696483BACKGROUND
  • Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer's disease: causes and clinical relevance. Lancet Neurol. 2017 Apr;16(4):311-322. doi: 10.1016/S1474-4422(17)30044-3.

    PMID: 28327340BACKGROUND
  • Lam AD, Zepeda R, Cole AJ, Cash SS. Widespread changes in network activity allow non-invasive detection of mesial temporal lobe seizures. Brain. 2016 Oct;139(Pt 10):2679-2693. doi: 10.1093/brain/aww198. Epub 2016 Jul 29.

    PMID: 27474219BACKGROUND
  • Rabinowicz AL, Starkstein SE, Leiguarda RC, Coleman AE. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):231-3. doi: 10.1097/00002093-200010000-00008.

    PMID: 11186602BACKGROUND
  • Zarea A, Charbonnier C, Rovelet-Lecrux A, Nicolas G, Rousseau S, Borden A, Pariente J, Le Ber I, Pasquier F, Formaglio M, Martinaud O, Rollin-Sillaire A, Sarazin M, Croisile B, Boutoleau-Bretonniere C, Ceccaldi M, Gabelle A, Chamard L, Blanc F, Sellal F, Paquet C, Campion D, Hannequin D, Wallon D; PHRC GMAJ Collaborators. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016 Aug 30;87(9):912-9. doi: 10.1212/WNL.0000000000003048. Epub 2016 Jul 27.

    PMID: 27466472BACKGROUND
  • Tai XY, Koepp M, Duncan JS, Fox N, Thompson P, Baxendale S, Liu JY, Reeves C, Michalak Z, Thom M. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016 Sep;139(Pt 9):2441-55. doi: 10.1093/brain/aww187. Epub 2016 Aug 7.

    PMID: 27497924BACKGROUND
  • Horvath A, Szucs A, Barcs G, Kamondi A. Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity. J Alzheimers Dis. 2017;56(3):1175-1183. doi: 10.3233/JAD-160994.

    PMID: 28128769BACKGROUND
  • Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012 May 10;74(3):467-74. doi: 10.1016/j.neuron.2012.03.023.

    PMID: 22578498BACKGROUND
  • McCurry SM, Logsdon RG, Teri L, Gibbons LE, Kukull WA, Bowen JD, McCormick WC, Larson EB. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol. 1999 Summer;12(2):53-9. doi: 10.1177/089198879901200203.

    PMID: 10483925BACKGROUND
  • Ownby RL, Peruyera G, Acevedo A, Loewenstein D, Sevush S. Subtypes of sleep problems in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2014 Feb;22(2):148-56. doi: 10.1016/j.jagp.2012.08.001. Epub 2013 Jan 11.

    PMID: 23567445BACKGROUND
  • Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013 May;70(5):587-93. doi: 10.1001/jamaneurol.2013.2334.

    PMID: 23479184BACKGROUND
  • Pavlova M. Circadian Rhythm Sleep-Wake Disorders. Continuum (Minneap Minn). 2017 Aug;23(4, Sleep Neurology):1051-1063. doi: 10.1212/CON.0000000000000499.

    PMID: 28777176BACKGROUND
  • Saeed Y, Abbott SM. Circadian Disruption Associated with Alzheimer's Disease. Curr Neurol Neurosci Rep. 2017 Apr;17(4):29. doi: 10.1007/s11910-017-0745-y.

    PMID: 28324298BACKGROUND
  • Foldvary-Schaefer NR, Waters TE. Sleep-Disordered Breathing. Continuum (Minneap Minn). 2017 Aug;23(4, Sleep Neurology):1093-1116. doi: 10.1212/01.CON.0000522245.13784.f6.

    PMID: 28777178BACKGROUND
  • Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. Sleep. 2013 Jul 1;36(7):1027-1032. doi: 10.5665/sleep.2802.

    PMID: 23814339BACKGROUND
  • Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33.

    PMID: 25405649BACKGROUND
  • Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009 Nov 13;326(5955):1005-7. doi: 10.1126/science.1180962. Epub 2009 Sep 24.

    PMID: 19779148BACKGROUND
  • Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-beta42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res. 2012 Dec;9(10):1119-25. doi: 10.2174/156720512804142840.

    PMID: 22742854BACKGROUND
  • Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med. 2012 Sep 5;4(150):150ra122. doi: 10.1126/scitranslmed.3004291.

    PMID: 22956200BACKGROUND
  • Pase MP, Himali JJ, Grima NA, Beiser AS, Satizabal CL, Aparicio HJ, Thomas RJ, Gottlieb DJ, Auerbach SH, Seshadri S. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017 Sep 19;89(12):1244-1250. doi: 10.1212/WNL.0000000000004373. Epub 2017 Aug 23.

    PMID: 28835407BACKGROUND
  • Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013 Dec;70(12):1544-51. doi: 10.1001/jamaneurol.2013.4215.

    PMID: 24145819BACKGROUND
  • Reynolds CF 3rd, Kupfer DJ, Taska LS, Hoch CC, Sewitch DE, Restifo K, Spiker DG, Zimmer B, Marin RS, Nelson J, et al. Sleep apnea in Alzheimer's dementia: correlation with mental deterioration. J Clin Psychiatry. 1985 Jul;46(7):257-61.

    PMID: 4008448BACKGROUND
  • Ancoli-Israel S, Klauber MR, Butters N, Parker L, Kripke DF. Dementia in institutionalized elderly: relation to sleep apnea. J Am Geriatr Soc. 1991 Mar;39(3):258-63. doi: 10.1111/j.1532-5415.1991.tb01647.x.

    PMID: 2005339BACKGROUND
  • Daulatzai MA. Evidence of neurodegeneration in obstructive sleep apnea: Relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. J Neurosci Res. 2015 Dec;93(12):1778-94. doi: 10.1002/jnr.23634. Epub 2015 Aug 24.

    PMID: 26301370BACKGROUND
  • Troussiere AC, Charley CM, Salleron J, Richard F, Delbeuck X, Derambure P, Pasquier F, Bombois S. Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1405-8. doi: 10.1136/jnnp-2013-307544. Epub 2014 May 14.

    PMID: 24828897BACKGROUND
  • Pornsriniyom D, Kim Hw, Bena J, Andrews ND, Moul D, Foldvary-Schaefer N. Effect of positive airway pressure therapy on seizure control in patients with epilepsy and obstructive sleep apnea. Epilepsy Behav. 2014 Aug;37:270-5. doi: 10.1016/j.yebeh.2014.07.005. Epub 2014 Aug 12.

    PMID: 25117208BACKGROUND
  • Sheth SA, Aronson JP, Shafi MM, Phillips HW, Velez-Ruiz N, Walcott BP, Kwon CS, Mian MK, Dykstra AR, Cole A, Eskandar EN. Utility of foramen ovale electrodes in mesial temporal lobe epilepsy. Epilepsia. 2014 May;55(5):713-724. doi: 10.1111/epi.12571. Epub 2014 Mar 7.

    PMID: 24605889BACKGROUND
  • Risse SC, Lampe TH, Bird TD, Nochlin D, Sumi SM, Keenan T, Cubberley L, Peskind E, Raskind MA. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord. 1990 Winter;4(4):217-25. doi: 10.1097/00002093-199040400-00003.

    PMID: 2264979BACKGROUND
  • Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM. Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels. Brain. 2017 Aug 1;140(8):2104-2111. doi: 10.1093/brain/awx148.

    PMID: 28899014BACKGROUND
  • Subota A, Pham T, Jette N, Sauro K, Lorenzetti D, Holroyd-Leduc J. The association between dementia and epilepsy: A systematic review and meta-analysis. Epilepsia. 2017 Jun;58(6):962-972. doi: 10.1111/epi.13744. Epub 2017 Apr 11.

    PMID: 28397967BACKGROUND
  • Malow A, Bowes RJ, Ross D. Relationship of temporal lobe seizures to sleep and arousal: a combined scalp-intracranial electrode study. Sleep. 2000 Mar 15;23(2):231-4.

    PMID: 10737340BACKGROUND
  • Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YA, Scheltens P. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord. 2010;29(5):432-7. doi: 10.1159/000278620. Epub 2010 May 26.

    PMID: 20502017BACKGROUND
  • McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly: a review of 94 patients. Epilepsia. 2002 Feb;43(2):165-9. doi: 10.1046/j.1528-1157.2002.24401.x.

    PMID: 11903463BACKGROUND
  • Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995 Sep-Oct;6(5):258-63. doi: 10.1159/000106956.

    PMID: 8528372BACKGROUND
  • Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.

    PMID: 22869752BACKGROUND
  • van Golde EG, Gutter T, de Weerd AW. Sleep disturbances in people with epilepsy; prevalence, impact and treatment. Sleep Med Rev. 2011 Dec;15(6):357-68. doi: 10.1016/j.smrv.2011.01.002. Epub 2011 Mar 24.

    PMID: 21439869BACKGROUND
  • Manni R, Terzaghi M. Comorbidity between epilepsy and sleep disorders. Epilepsy Res. 2010 Aug;90(3):171-7. doi: 10.1016/j.eplepsyres.2010.05.006. Epub 2010 May 31.

    PMID: 20570109BACKGROUND

Related Links

MeSH Terms

Conditions

Alzheimer DiseaseEpilepsySleep Wake Disorders

Interventions

Polysomnography

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Monitoring, PhysiologicDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Wim Van Paesschen, MD PhD

    UZ and KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
FACTORIAL
Model Details: The investigators will perform 48-hour ambulatory scalp-EEG and polysomnography in 100 participants with Alzheimer disease and 30 age-and gender-matched healthy participants. The investigators will determine the prevalence of 1.) epileptic discharges and epileptic seizures, 2.) sleep wake disorders and 3.) the interaction of epilepsy and sleep wake disorders in these two groups. A subgroup of 15 of these 100 participants with Alzheimer disease, with interictal epileptic spikes or sleep wake disorders (e.g., frequent nocturnal awakenings) will be invited to undergo an invasive EEG study with foramen ovale electrodes to determine the prevalence of hippocampal seizures, which are usually clinically silent and not detected with scalp EEG.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Doctor

Study Record Dates

First Submitted

July 24, 2018

First Posted

August 6, 2018

Study Start

December 1, 2020

Primary Completion

September 30, 2024

Study Completion

September 30, 2024

Last Updated

October 13, 2023

Record last verified: 2023-10

Locations